knowledge -WSS

knowledge

author：fashion 2025-09-27 23:03:40 - browse：229

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： YouTube cracks down on misinformation on cancer treatment

focus

WSS

Dozens dead from Maui wildfires: What we know about the victims

Schizophrenia gene found to be linked to cells' energy dysfunction

Idaho college killings prosecutors challenge defense's grand jury claims

Schizophrenia gene found to be linked to cells' energy dysfunction

BMS, looking to build heart drug business, turns to AI for diagnosis

Mark Cuban is blaming the wrong people for high drug costs

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

In Memoriam: Notable people who died in 2023

Hospitals are dialing back on venture capital investing

23andMe had bad news about my health. I wish a person had delivered it

Dozens dead from Maui wildfires: What we know about the victims

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biden administration begins canceling student loan debt for 804,000 borrowers

Walensky prepares to leave CDC — and Congress — behind

White House touts steps to stem shortages of cancer treatments

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How housing is health care on Long Island

Wikipedia

Telehealth for opioid use disorder is lifesaving

PEPFAR is under serious threat — and so is global health

Maui wildfire now ranks as the fifth

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Schizophrenia gene found to be linked to cells' energy dysfunction

Popular nasal decongestant doesn't actually relieve congestion

explore

hotspot

focus

hotspot